By
FRANKFURT: Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.
The Swiss drugmaker said in a statement that it expects 2025 operating income, adjusted for special items, to grow by a “low double-digit” percentage.
Novartis agrees to acquire Anthos for up to $3.1 billion
It had previously projected “high single to low double-digit” growth, compared with a 22% increase in 2024.